

August 15, 2022

To whom it may concern:

Company Name	TOHO HOLDINGS CO., LTD.
Corporate Representative	Atsushi Udoh, Representative Director, CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Communications and Investor Relations Division (TEL: 81-3-6838-2803)

Notice Regarding Marketing Approvals for  
1 Ingredient / 2 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has received approvals for marketing of 1 ingredient / 2 products of generic drugs today on August 15, 2022 as below.

Products list approved for marketing

Class	Product Name	Original Brand Name
V2-receptor antagonist	Tolvaptan OD tablets 7.5mg/15mg “KMP”	Samsca® OD tablets 7.5mg/15mg